Pulse Biosciences, Inc. (NASDAQ: PLSE) Q4 2024 Earnings Call Transcript March 27, 2025 Pulse Biosciences, Inc. beats earnings ...

Investing.com — Pulse Biosciences, Inc. (NASDAQ: PLSE )周四公布的2024年第四季度亏损超出预期，导致该公司股价在盘后交易中下跌2%。 这家医疗技术公司第四季度调整后每股亏损0.31美元，未能达到分析师预估的每股亏损0.24美元。该季度公司未报告任何收入。

Philip Taylor; Investor Relations; Pulse Biosciences Inc. Paul Laviolette; Co-Chairman of the Board, President, Chief Executive Officer; Pulse Biosciences Inc. Jon S ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the first procedure with ...

On Wednesday, March 5, 2025, Pulse Biosciences (NASDAQ: PLSE) presented at the TD Cowen 45th Annual Healthcare Conference, highlighting its cutting-edge nanosecond Pulsed Field Ablation (nsPFA ...